AIM ImmunoTech Reports Third Quarter 2024 Financial Results and Provides Corporate Update

– Continued execution across Ampligen® clinical development programs in areas with critical unmet needs, especially in the high-value pancreatic cancer space

– Driving significant momentum with positive clinical trial data, underscoring big pharma collaboration and commercialization opportunities